Recombinant Human P16-INK4a #abs01267

abs01267-10ug

1-2 Weeks

138

abs01267-50ug

1-2 Weeks

344

abs01267-1mg

1-2 Weeks

3079

Species

Human

Source

Escherichia coli.

Format

The concentrated solution in PBS with a pH of 7.4 was filtered through a 0.2 μm membrane and then lyophilized. To create a similar content with a slightly different wording, the original text can be rewritten as follows: The solution, which had a high concentration, was dissolved in PBS and filtered using a membrane with a pore size of 0.2 μm. Next, the solution was subjected to lyophilization to obtain a dry powder. The pH of the solution was maintained at 7.4 throughout the process.

Properties

aa_sequence

ARGRVEEVRA PNSYGRRPIQ LLEAGALPNA MEPAAGSSME VMMMGSARVA AREEGVLRLA NCADPATLTR PVHDAAREGF LDTLVVLHRA GARLDVRDAW GRLPVDLAEE LGHRDVARYL RAAAGGTRGS NHARIDAAEG PSDIPD EGALARPNAH.

Concentration

> 96 % by SDS-PAGE and HPLC analyses.

Endotoxin_level

The LAL method determined that the Recombinant Human P16-INK4a contains less than 1 EU/μg. To create similar content, one could rearrange this information and state that the content is based on the original text.

Reconstitution

To ensure proper mixing, we suggest briefly centrifuging the vial before opening it. Reconstitute the contents in either sterile distilled water or an aqueous buffer containing 0.1% BSA. Aim for a concentration range of 0.1-1.0 mg/mL. It is advisable to divide the stock solutions into smaller working aliquots and store them at temperatures below -20 °C. For further dilution, utilize appropriate buffered solutions.

Stability & Storage

For optimal storage conditions, it is recommended to keep this lyophilized preparation at -20 °C for extended periods, with the additional preference of ensuring it remains desiccated. Stability can still be maintained at 2-8 °C, but for a shorter duration after reconstitution, usually up to one week. To maximize the longevity of the reconstituted preparation, it is advised to divide it into suitable working aliquots and store them at temperatures ranging from -20 °C to -70 °C. It is crucial to avoid subjecting the preparation to repeated freeze/thaw cycles.

References

References

1. Buda G, Maggini V, Galimberti S, et al. 2007. Leuk Res, 31: 569-70.

2. Komiya A, Suzuki H, Aida S, et al. 1995. Jpn J Cancer Res, 86: 622-5.

3. Jares P, Fernandez PL, Nadal A, et al. 1997. Oncogene, 15: 1445-53.

4. Mori T, Miura K, Aoki T, et al. 1994. Cancer Res, 54: 3396-7.